- Perimenopause and menopause are different states: perimenopause is the transition, with cycles still happening but becoming erratic, while menopause is dated retrospectively from twelve consecutive months after the final menstrual period. Almost all of the trial evidence sits in the postmenopausal group, not the transition.
- Three peptides have genuine grade A evidence in menopausal women, all in bone: teriparatide (1,637 postmenopausal women), abaloparatide (2,463) and salmon calcitonin (1,255). Their evidence base is female by design, because postmenopausal osteoporosis is the approved indication.
- Bremelanotide is approved only for premenopausal women with hypoactive sexual desire disorder. Postmenopausal women were not in the approved population, so using the approval as evidence for menopausal libido reverses what the label actually says.
- For the research compounds most often marketed at perimenopausal women, including growth-hormone secretagogues and most repair peptides, no study has stratified outcomes by menopausal stage. That is recorded here as unstudied rather than filled in.
Search for peptides and menopause and you will find a great deal of confident writing. Very little of it distinguishes between the two things a reader in her forties or fifties actually needs to separate: compounds that were tested in women at this life stage, and compounds that were tested in someone else and are being sold to her anyway. This piece sorts the field into those two piles.
Nothing here is medical advice or a dosing recommendation, and the research compounds discussed are for laboratory research use only. Decisions about menopausal symptoms belong with a clinician who knows your history.
Perimenopause and menopause are not the same population
The distinction matters more than the shared vocabulary suggests. Perimenopause is the transition itself: cycles still occur but become irregular, and estrogen does not decline smoothly, it swings. Menopause is a single point in time, dated retrospectively as twelve consecutive months after the final menstrual period, and everything after it is postmenopause. The hormonal environments are genuinely different, and a woman at 46 with erratic cycles and a woman at 58 five years past her last period are not interchangeable study subjects.
Where the evidence is real: bone
There is one corner of peptide medicine where the female evidence is not a gap at all, and it exists for a structural reason. Postmenopausal osteoporosis is a women's condition, so the pivotal trials had to enroll women. The result is the reverse of the usual pattern in this database: the female evidence base is the primary one, and the male data is the afterthought.
| Compound | Pivotal trial population | Reported result |
|---|---|---|
| Teriparatide | 1,637 postmenopausal women with prior vertebral fracture (Neer 2001) | Reduced new vertebral fracture risk (RR 0.35) and non-vertebral fragility fracture (RR 0.47) vs placebo |
| Abaloparatide | 2,463 postmenopausal women at high fracture risk (ACTIVE, Miller 2016) | 86% relative reduction in new morphometric vertebral fractures vs placebo over 18 months, with a teriparatide comparator arm |
| Calcitonin (salmon) | 1,255 postmenopausal women with established osteoporosis (PROOF, 5 years) | 33% reduction in new vertebral fracture at 200 IU daily, but not at 100 or 400 IU |
The calcitonin entry is worth dwelling on, because it is the most honest thing in the table. Its dose response did not behave as a real effect should: the middle dose reduced fractures and the highest dose did not. A later pooled review of randomized trials found more malignancies among calcitonin-treated participants than placebo (4.1% versus 2.9%), and European regulators subsequently withdrew the osteoporosis indication while the FDA restricted it to patients for whom other treatments are unsuitable. Good female enrollment does not guarantee a good answer. It guarantees a real one.
The approval that gets read backwards
Bremelanotide is frequently cited as evidence that a peptide can help menopausal libido. The label says the opposite. It is approved for premenopausal women with acquired, generalized hypoactive sexual desire disorder. Postmenopausal women were not the studied population and are not in the approved indication.
An approval is the strongest evidence a compound can carry, so borrowing it across a population boundary is the most efficient way to make a weak claim look strong. "FDA-approved for female sexual desire" is true. "Therefore it is the evidence-backed option for menopausal libido" is not, because the trials that produced the approval deliberately excluded that group. Always check which women were in the trial, not just that women were.
The adjacent evidence: metabolic and skin
Two other areas have real female data that is relevant to this life stage without being about it, and the distinction is worth holding onto.
- Incretins. The obesity trials behind semaglutide and tirzepatide were majority female, deliberately so: enrollment in the SURMOUNT program was capped at 70% women. That is genuine female evidence for weight outcomes. It is not menopause evidence, because results were not stratified by menopausal stage, and the midlife weight redistribution many women are actually asking about was not the endpoint.
- Copper peptides. GHK-Cu has cosmetic dermatology studies that enrolled peri- and postmenopausal women for skin-aging endpoints, which is why its menopause field reads evidence rather than unstudied. The caveat is that these are small topical cosmetic studies, not the kind of trial that supports a systemic claim.
Where the answer is simply that nobody looked
That is the end of the list. For the compounds most heavily marketed to women in the menopausal transition, the honest position is an absence. Growth-hormone secretagogues are the clearest case: growth-hormone physiology is strongly sex-differentiated and estrogen blunts the liver's IGF-1 response, so menopausal status is exactly the variable that should have been measured, and in ipamorelin and CJC-1295 it was not. The same holds for the repair peptides, the sleep peptides, and the longevity compounds: not contradicted, not supported, simply unexamined at this life stage.
This database records that as unstudied, which is a claim about the literature rather than about the compound. It does not mean unsafe and it does not mean ineffective. It means that if someone tells you what a compound does for perimenopausal women, they are extrapolating from a population that did not include them, and you are entitled to ask from where. The habit of asking is covered in why almost every peptide study left women out.
One last thing worth knowing, because it cuts against the framing of this whole category: the best-understood mechanism in menopause medicine is a peptide, and the drugs that act on it are not. That story is in why hot flushes happen.